BUCCOTHERM: Clinical Trial to Determine the Effect of a Mouthwash on the Preservation of the Ecology of the Oral Microbiome and Its Compatibility With Health

Sponsor
Rennes University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04973358
Collaborator
(none)
220
1
2
24
9.2

Study Details

Study Description

Brief Summary

The microbiota of the human body is essential to life, and plays an essential role in the protection and development of various pathological conditions. There is a symbiotic or mutualistic relationship between humans and their microbiota. However, when the microbiota becomes dysbiotic, it is associated with pathological conditions. In the oral cavity, dysbiosis is responsible for caries and periodontal pathologies, but other associations have been demonstrated or are suspected with distant pathologies (rheumatoid arthritis, Alzheimer's disease). Mouthwashes are used therapeutically or daily to maintain oral health. The main studies reporting their effects on the ecology of the oral microbiota are for the most part limited to Pasteurian culture techniques (40% of bacteria are not yet cultivable). The advent of new generations of sequencing allows to overcome this limitation and to explore the complexity of bacterial communities, i.e. the symbiosis or dysbiosis of the entire bacterial ecosystem. The control of the oral microbiota to prevent pathologies requires a better knowledge of the oral microbial ecology and will allow the development of new approaches that consider the process of biofilm formation and the disruption of bacterial communication networks. The effects of daily mouthwash must therefore be studied at the level of the entire bacterial community.

Condition or Disease Intervention/Treatment Phase
  • Other: buccotherm mouthwash
  • Other: placebo mouthwash
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
220 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
BUCCOTHERM : Randomized Clinical Trial to Determine the Effect of a Mouthwash on the Preservation of the Ecology of the Oral Microbiome and Its Compatibility With Health
Anticipated Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: BuccoTherm

buccotherm mouthwash

Other: buccotherm mouthwash
twice a day for 14 weeks

Placebo Comparator: Placebo

placebo mouthwash

Other: placebo mouthwash
twice a day for 14 weeks

Outcome Measures

Primary Outcome Measures

  1. Commensal species of the oral microbiota [week 14]

    Change from baseline in commensal species at 14 weeks

  2. Alpha and beta diversity of the oral microbiota [week 14]

    Change from baseline in alpha and beta diversity at 14 weeks

  3. Coefficient of dysbiosis/symbiosis of the oral microbiota [week 14]

    Change from baseline in coefficient of dysbiosis/symbiosis at 14 weeks

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18 years of age or older:

  • with at least 20 permanent natural teeth, excluding crowns;

  • affiliated to a social security system;

  • having received information about the protocol and having given their free, informed and written consent.

Exclusion Criteria:
  • with periodontitis in the month prior to inclusion;

  • with significant carious lesions deeply modifying the oral microbiota in the month prior to inclusion;

  • having undergone oral surgical treatment within 3 months prior to inclusion;

  • wearing orthodontic appliances;

  • having undergone periodontal procedures in the month prior to inclusion;

  • suffering from severe chronic pathologies deemed incompatible with study entry;

  • allergic to one of the swab components;

  • allergic to any of the components of the BUCCOTHERM mouthwash or the placebo;

  • on drugs that may cause gingival hypertrophy, such as Hydantoins (phenytoin), Dihydropyridines, Diltiazem or Ciclosporin;

  • Medications that can cause gingival bleeding (anticoagulants, antiplatelet agents and aspirin);

  • Antibiotic therapy or professional scaling in the month prior to inclusion;

  • having used oral or topical antibiotics, antiseptics and/or antifungals (e.g., mouthwash, dental gels, etc.) in the month prior to inclusion.

  • Subjects with poor written and spoken French language skills;

  • previously included in the BUCCOTHERM study;

  • simultaneously participating in another trial that may interfere with the conduct of the BUCCOTHERM study or in a period of exclusion after participation in another clinical study;

  • protected persons (adults under legal protection (legal guardianship, curatorship, tutorship), persons deprived of liberty, pregnant or breastfeeding women, women of childbearing age without effective contraception (estrogen-progestin treatments, IUD, tubal ligation), minors.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Rennes Rennes France

Sponsors and Collaborators

  • Rennes University Hospital

Investigators

  • Principal Investigator: Meuric Vincent, CHU Rennes

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rennes University Hospital
ClinicalTrials.gov Identifier:
NCT04973358
Other Study ID Numbers:
  • 35RC21_9796_BUCCOTHERM
  • 2021-A01541-40
First Posted:
Jul 22, 2021
Last Update Posted:
Aug 27, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Rennes University Hospital

Study Results

No Results Posted as of Aug 27, 2021